Balancing AID and DNA repair during somatic hypermutation - PubMed

Review

Balancing AID and DNA repair during somatic hypermutation

Man Liu et al. Trends Immunol. 2009 Apr.

Abstract

Somatic hypermutation (SHM) of Ig genes in B cells is crucial for antibody affinity maturation. The reaction is initiated by cytosine deamination of Ig loci by activation induced deaminase (AID) and is completed by error-prone DNA repair enzyme processing of AID-generated uracils. The mechanisms that target SHM specifically to Ig loci are poorly understood. Recently, it has been demonstrated that although AID preferentially targets Ig loci, it acts surprisingly widely on non-Ig loci, many of which are protected from mutation accumulation by high-fidelity DNA repair. We propose that breakdown of this high fidelity repair process helps explain oncogene mutations observed in B-cell tumors, and further, that many oncogenes are vulnerable to AID-mediated DNA breaks and translocations in normal activated B cells.

Similar articles

• Identification of core DNA elements that target somatic hypermutation.

  Kohler KM, McDonald JJ, Duke JL, Arakawa H, Tan S, Kleinstein SH, Buerstedde JM, Schatz DG. Kohler KM, et al. J Immunol. 2012 Dec 1;189(11):5314-26. doi: 10.4049/jimmunol.1202082. Epub 2012 Oct 19. J Immunol. 2012. PMID: 23087403 Free PMC article.

• Activation-induced cytidine deaminase in antibody diversification and chromosome translocation.

  Gazumyan A, Bothmer A, Klein IA, Nussenzweig MC, McBride KM. Gazumyan A, et al. Adv Cancer Res. 2012;113:167-90. doi: 10.1016/B978-0-12-394280-7.00005-1. Adv Cancer Res. 2012. PMID: 22429855 Free PMC article. Review.

• Mutating for Good: DNA Damage Responses During Somatic Hypermutation.

  Pilzecker B, Jacobs H. Pilzecker B, et al. Front Immunol. 2019 Mar 12;10:438. doi: 10.3389/fimmu.2019.00438. eCollection 2019. Front Immunol. 2019. PMID: 30915081 Free PMC article. Review.

• AID targeting in antibody diversity.

  Pavri R, Nussenzweig MC. Pavri R, et al. Adv Immunol. 2011;110:1-26. doi: 10.1016/B978-0-12-387663-8.00005-3. Adv Immunol. 2011. PMID: 21762814 Review.

• Restriction of AID activity and somatic hypermutation by PARP-1.

  Tepper S, Mortusewicz O, Członka E, Bello A, Schmidt A, Jeschke J, Fischbach A, Pfeil I, Petersen-Mahrt SK, Mangerich A, Helleday T, Leonhardt H, Jungnickel B. Tepper S, et al. Nucleic Acids Res. 2019 Aug 22;47(14):7418-7429. doi: 10.1093/nar/gkz466. Nucleic Acids Res. 2019. PMID: 31127309 Free PMC article.

Cited by

• Identification of core DNA elements that target somatic hypermutation.

  Kohler KM, McDonald JJ, Duke JL, Arakawa H, Tan S, Kleinstein SH, Buerstedde JM, Schatz DG. Kohler KM, et al. J Immunol. 2012 Dec 1;189(11):5314-26. doi: 10.4049/jimmunol.1202082. Epub 2012 Oct 19. J Immunol. 2012. PMID: 23087403 Free PMC article.

• Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments.

  Pálinkás HL, Békési A, Róna G, Pongor L, Papp G, Tihanyi G, Holub E, Póti Á, Gemma C, Ali S, Morten MJ, Rothenberg E, Pagano M, Szűts D, Győrffy B, Vértessy BG. Pálinkás HL, et al. Elife. 2020 Sep 21;9:e60498. doi: 10.7554/eLife.60498. Elife. 2020. PMID: 32956035 Free PMC article.

• Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination.

  Hasham MG, Donghia NM, Coffey E, Maynard J, Snow KJ, Ames J, Wilpan RY, He Y, King BL, Mills KD. Hasham MG, et al. Nat Immunol. 2010 Sep;11(9):820-6. doi: 10.1038/ni.1909. Epub 2010 Jul 25. Nat Immunol. 2010. PMID: 20657597 Free PMC article.

• A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements.

  McCafferty N, Stewart JP, Darzentas N, Gazdova J, Catherwood M, Stamatopoulos K, Langerak AW, Gonzalez D. McCafferty N, et al. Haematologica. 2023 May 1;108(5):1313-1321. doi: 10.3324/haematol.2022.281928. Haematologica. 2023. PMID: 36579446 Free PMC article.

• Repression of human activation induced cytidine deaminase by miR-93 and miR-155.

  Borchert GM, Holton NW, Larson ED. Borchert GM, et al. BMC Cancer. 2011 Aug 10;11:347. doi: 10.1186/1471-2407-11-347. BMC Cancer. 2011. PMID: 21831295 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program